Pfizer shares positive overall survival results for Elrexfio in multiple myeloma

17 Jun 2024
pmlive.com
Phase 2Drug ApprovalClinical ResultImmunotherapyAccelerated Approval
Pfizer shares positive overall survival results for Elrexfio in multiple myeloma
Preview
Source: PMLiVE
Pfizer has shared promising phase 2 results of its Elrexfio (elranatamab-bcmm) monotherapy in patients with heavily pre-treated relapsed or refractory multiple myeloma (RRMM) as part of its ongoing MagentisMM clinical development programme.
New data from the MagnetisMM-3 trial was presented at the European Hematology Association (FHA) Hybrid Congress.
Responsible for more than 187,000 new cases globally every year, multiple myeloma (MM) is an aggressive and incurable blood cancer that affects plasma cells in the bone marrow.
The MagentisMM clinical development programme has been investigating the use of Elrexfio in patients with MM, including RRMM and newly diagnosed MM, in comparison to current standards of care, both as a monotherapy and in combination with standard or novel therapies.
The phase 2 open-label, multicentre study has been evaluating subcutaneous Elrexfio monotherapy as two step-up priming doses followed by a weekly 76mg injection in patients with MM who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-cluster of differentiation 38 antibody.
Elrexfio is a subcutaneously delivered bispecific antibody that works to bind to B-cell maturation antigen, which is highly expressed on the surface of multiple myeloma cells, and cluster of differentiation (CD)3 receptors found on the surface of T-cells, which activates the T-cells to kill myeloma cells.
Results from the study showed that Elrexfio demonstrated a median overall survival of 24.6 months and a median progression-free survival of 17.2 months in RRMM patients, with the safety and tolerability of the treatment being consistent with previous studies.
Roger Dansey, chief development officer, oncology, Pfizer, commented: “The latest results from MagnetisMM-3 reinforce the very promising efficacy observed with Elrexfio in a relapsed or refractory setting, with deep and durable responses and… the longest reported median progression-free survival among B-cell maturation antigen bispecific antibodies.”
Based on the results of the MagentisMM-3 trial, Elrexfio was granted approval from the European Commission in December 2023 to treat adults with RRMM who have received at least three prior lines of therapy.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.